innoscripta SE, a provider of the Clusterix software platform for R&D management, announced its financial results for the first half of 2026, revealing significant growth and strategic progress. The company reported revenue of EUR 63.1 million, a 43% increase compared to the same period in 2025. Adjusted EBIT rose by 49% year-on-year to EUR 36.4 million, excluding EUR 535 thousand in non-recurring expenses related to corporate restructuring and group establishment. The adjusted EBIT margin reached 57.7% (unadjusted: 56.9%).
The company's growth is partly attributed to the German R&D tax allowance (Forschungszulage), which has been a key driver. The number of innoscripta customers has grown to over 2,900 in the first half of the year. This indicates a strong demand for its services, as businesses seek to optimize their R&D tax benefits.
In the first half of 2026, innoscripta further strengthened Clusterix as its central infrastructure for project structuring, data management, and application submissions. This enhancement enables automated data validation, higher data quality, and faster, more standardized processes. It also establishes consistent workflows across different markets, providing a technological foundation for international scaling. This is crucial as the company expands into new regions.
The company's international expansion is progressing as planned. innoscripta has successfully entered the French market with a location near Toulouse and has already secured customers. In the UK, it opened an office in Manchester, effective July 1, 2026. Additionally, the company is now active in the US, a high-growth market, and has begun serving its first companies there. The flexibility of Clusterix in adapting to different regulatory requirements has enabled efficient entry into new markets.
These developments are part of innoscripta's broader regional expansion strategy, which also includes the opening of an office in Hamburg. The company's ability to adapt its platform to various regulatory environments positions it well for continued global growth.
Looking ahead, the Management Board confirms its guidance for the current financial year, expecting Group revenue of at least EUR 140 million and EBIT of at least EUR 80 million, assuming consistent timing of customer applications' submission and approval. This guidance reflects confidence in the company's growth trajectory and market opportunities.
The detailed financial figures for the first half of 2026 are available in the Half-Year Report on the company's website in the Investors section. Additionally, innoscripta will host a virtual earnings call on its H1 2026 results today at 3:00 p.m. CEST, with the invitation and dial-in link available on the company's website under Investor Events.
innoscripta SE offers Clusterix, a scalable software platform for the structured organization and management of research and development activities. Companies use Clusterix to efficiently manage innovation projects, digitize internal processes, and make their R&D activities transparent and scalable, which is increasingly important in a competitive business environment.
The strong first-half performance and strategic expansion highlight innoscripta's position in the business services industry, particularly in R&D tax consultancy and software solutions. For businesses, this underscores the growing importance of efficient R&D management platforms in maximizing tax benefits and streamlining operations across international borders.
